These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Anticoagulation in patients with atrial fibrillation]. Mügge A. Herz; 1996 Feb; 21(1):28-36. PubMed ID: 8647577 [Abstract] [Full Text] [Related]
23. The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients. Poli D, Antonucci E, Marcucci R, Mannini L, Falciani M, Abbate R, Gensini GF, Prisco D. Int J Cardiol; 2009 Feb 06; 132(1):109-13. PubMed ID: 18180057 [Abstract] [Full Text] [Related]
24. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M, AFFIRM Investigators. Am Heart J; 2005 Apr 06; 149(4):650-6. PubMed ID: 15990748 [Abstract] [Full Text] [Related]
25. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. Nieuwlaat R, Connolly BJ, Hubers LM, Cuddy SM, Eikelboom JW, Yusuf S, Connolly SJ, ACTIVE Investigators. Thromb Res; 2012 Jun 06; 129(6):715-9. PubMed ID: 21924760 [Abstract] [Full Text] [Related]
26. Gender differences of bleeding and stroke risk in very old atrial fibrillation patients on VKA treatment: results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Poli D, Antonucci E, Testa S, Ageno W, Palareti G, FCSA (Italian Federation of Anticoagulation Clinics). Thromb Res; 2013 Jan 06; 131(1):12-6. PubMed ID: 23141847 [Abstract] [Full Text] [Related]
32. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Thromb Haemost; 2009 Feb 06; 101(2):367-72. PubMed ID: 19190823 [Abstract] [Full Text] [Related]
33. [INTERNATIONAL NORMALIZED RATIO VALUES AND HEMORRHAGE IN HOSPITALIZED PATIENTS STARTING WARFARIN THERPY: AN OBSERVATIONAL STUDY]. Abadi U, Ellis MH. Harefuah; 2015 Aug 06; 154(8):490-3, 541-2. PubMed ID: 26480611 [Abstract] [Full Text] [Related]
37. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation. Nairooz R, Sardar P, Pino M, Aronow WS, Sewani A, Mukherjee D, Paydak H, Maskoun W. Int J Cardiol; 2015 Aug 06; 187():345-53. PubMed ID: 25839640 [Abstract] [Full Text] [Related]
38. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Eur Heart J; 2011 Oct 06; 32(19):2387-94. PubMed ID: 21873708 [Abstract] [Full Text] [Related]
40. Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion. Roijer A, Eskilsson J, Olsson B. Eur Heart J; 2000 May 06; 21(10):837-47. PubMed ID: 10781356 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]